European Journal of Clinical Pharmacology

, Volume 63, Issue 10, pp 959–971 | Cite as

Digoxin and mortality in atrial fibrillation: a prospective cohort study

  • Pär Hallberg
  • Johan Lindbäck
  • Bertil Lindahl
  • Ulf Stenestrand
  • Håkan Melhus
  • for the RIKS-HIA group
Pharmacoepidemiology and Prescription

Abstract

Objective

The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study showed that rhythm-control treatment of patients with atrial fibrillation (AF) offered no survival advantage over a rate-control strategy. In a subgroup analysis of that study, it was found that digoxin increased the death rate [relative risk (RR) = 1.42), but it was suggested that this may have been attributable to prescription of digoxin for patients at greater risk of death, such as those with congestive heart failure (CHF). No study has investigated a priori the effect of digoxin on mortality in patients with AF. This study aimed to address this question.

Methods

Using data from the Registry of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA), we studied the 1-year mortality among patients admitted to coronary care units with AF, CHF, or AF+CHF with or without digoxin (n = 60,764) during 1995–2003. Adjustment for differences in background characteristics and other medications and treatments was made by propensity scoring.

Results

Twenty percent of patients with AF without CHF in this cohort were discharged with digoxin. This group had a higher mortality rate than the corresponding group not given digoxin [adjusted RR 1.42 (95% CI 1.29–1.56)], whereas no such difference was seen among patients with CHF with or without AF, although these patients had a nearly three-times higher mortality.

Conclusion

The results suggest that long-term therapy with digoxin is an independent risk factor for death in patients with AF without CHF.

Keywords

Digoxin Atrial fibrillation Heart failure Mortality RIKS-HIA 

References

  1. 1.
    Garg R, Gorlin R, Smith T, Yusuf S, on behalf of the Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525–533CrossRefGoogle Scholar
  2. 2.
    Hornestam B, on behalf of the Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group (1997) Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 18(4):649–654Google Scholar
  3. 3.
    Adams KF Jr, Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA, Gheorghiade M (2005) Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 46(3):497–504PubMedCrossRefGoogle Scholar
  4. 4.
    Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS (2004) Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 109(19):2290–2295PubMedCrossRefGoogle Scholar
  5. 5.
    Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG (2004) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109(12):1509–1513PubMedCrossRefGoogle Scholar
  6. 6.
    Eichhorn EJ, Gheorghiade M (2002) Digoxin. Prog Cardiovasc Dis 44(4):251–266PubMedCrossRefGoogle Scholar
  7. 7.
    Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ (1987) Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 106(4):503–506PubMedGoogle Scholar
  8. 8.
    Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 22(20):1852–1923PubMedCrossRefGoogle Scholar
  9. 9.
    Gheorghiade M, Ferguson D (1991) Digoxin. A neurohormonal modulator in heart failure? Circulation 84(5):2181–2186PubMedGoogle Scholar
  10. 10.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305PubMedCrossRefGoogle Scholar
  11. 11.
    Gold H, Cattell M, Greiner T (1953) Clinical pharmacology of digoxin. J Pharmacol Exp Ther (109):45–47PubMedGoogle Scholar
  12. 12.
    Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL (1995) Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 16(4):521–528PubMedGoogle Scholar
  13. 13.
    Jaeschke R, Oxman AD, Guyatt GH (1990) To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med 88(3):279–286PubMedCrossRefGoogle Scholar
  14. 14.
    Joffe MM, Rosenbaum PR (1999) Invited commentary: propensity scores. Am J Epidemiol 150(4):327–333PubMedGoogle Scholar
  15. 15.
    Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, Vertongen P, Bergez B, Vandekerckhove Y (1997) Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 18(4):643–648PubMedGoogle Scholar
  16. 16.
    Khairy P, Nattel S (2002) New insights into the mechanisms and management of atrial fibrillation. Cmaj 167(9):1012–1020PubMedGoogle Scholar
  17. 17.
    Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, Kim EJ, Kim SH, Cho SK, Kim SS (1995) Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 75(1):88–90PubMedCrossRefGoogle Scholar
  18. 18.
    Lader E, Egan D, Hunsberger S, Garg R, Czajkowski S, McSherry F (2003) The effect of digoxin on the quality of life in patients with heart failure. J Card Fail 9(1):4–12PubMedCrossRefGoogle Scholar
  19. 19.
    Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM (2004) Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291(17):2092–2099PubMedCrossRefGoogle Scholar
  20. 20.
    Macaubas C, de Klerk NH, Holt BJ, Wee C, Kendall G, Firth M, Sly PD, Holt PG (2003) Association between antenatal cytokine production and the development of atopy and asthma at age 6 years. Lancet 362(9391):1192–1197PubMedCrossRefGoogle Scholar
  21. 21.
    Norgaard A, Bagger JP, Bjerregaard P, Baandrup U, Kjeldsen K, Thomsen PE (1988) Relation of left ventricular function and Na,K-pump concentration in suspected idiopathic dilated cardiomyopathy. Am J Cardiol 61(15):1312–1315PubMedCrossRefGoogle Scholar
  22. 22.
    Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329(1):1–7PubMedCrossRefGoogle Scholar
  23. 23.
    Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB (2006) Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27(1):65–75PubMedCrossRefGoogle Scholar
  24. 24.
    Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289(7):871–878PubMedCrossRefGoogle Scholar
  25. 25.
    Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347(18):1403–1411PubMedCrossRefGoogle Scholar
  26. 26.
    Redfors A (1971) The effect of different digoxin doses on subjective symptoms and physical working capacity in patients with atrial fibrillation. Acta Med Scand 190(4):307–320PubMedGoogle Scholar
  27. 27.
    Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika (70):41–55CrossRefGoogle Scholar
  28. 28.
    Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127(8 Pt 2):757–763PubMedGoogle Scholar
  29. 29.
    Ruelaz RA, Rahimtoola SH (2005) Was it digoxin toxicity?...very likely. J Card Fail 11(2):87–90PubMedCrossRefGoogle Scholar
  30. 30.
    Spargias KS, Hall AS, Ball SG (1999) Safety concerns about digoxin after acute myocardial infarction. Lancet 354(9176):391–392PubMedCrossRefGoogle Scholar
  31. 31.
    Steimer W, Muller C, Eber B (2002) Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem 48(3):507–516PubMedGoogle Scholar
  32. 32.
    Stenestrand U, Tabrizi F, Lindback J, Englund A, Rosenqvist M, Wallentin L (2004) Comorbidity and myocardial dysfunction are the main explanations for the higher 1-year mortality in acute myocardial infarction with left bundle-branch block. Circulation 110(14):1896–1902PubMedCrossRefGoogle Scholar
  33. 33.
    Stenestrand U, Wallentin L (2002) Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. Lancet 359(9320):1805–1811PubMedCrossRefGoogle Scholar
  34. 34.
    Stenestrand U, Wallentin L (2001) Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285(4):430–436PubMedCrossRefGoogle Scholar
  35. 35.
    Stenestrand U, Wallentin L (2003) Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch Intern Med 163(8):965–971PubMedCrossRefGoogle Scholar
  36. 36.
    Tauke J, Goldstein S, Gheorghiade M (1994) Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of the angiotensin Converting Enzyme) trials. Prog Cardiovasc Dis 37(1):49–58PubMedCrossRefGoogle Scholar
  37. 37.
    Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK (1993) Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 22(4):955–962PubMedCrossRefGoogle Scholar
  38. 38.
    Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353(22):2335–2341PubMedCrossRefGoogle Scholar
  39. 39.
    Vardas PE, Kanoupakis EM, Kochiadakis GE, Simantirakis EN, Marketou ME, Chlouverakis GI (1998) Effects of long-term digoxin therapy on heart rate variability, baroreceptor sensitivity, and exercise capacity in patients with heart failure. Cardiovasc Drugs Ther 12(1):47–55PubMedCrossRefGoogle Scholar
  40. 40.
    Wills P, Fastbom J, Claesson CB, Cornelius C, Thorslund M, Winblad B (1996) Use of cardiovascular drugs in an older Swedish population. J Am Geriatr Soc 44(1):54–60PubMedGoogle Scholar
  41. 41.
    Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825–1833PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Pär Hallberg
    • 1
  • Johan Lindbäck
    • 2
  • Bertil Lindahl
    • 2
  • Ulf Stenestrand
    • 3
  • Håkan Melhus
    • 1
  • for the RIKS-HIA group
  1. 1.Department of Medical Sciences, Clinical PharmacologyUppsala University Hospital, Uppsala UniversityUppsalaSweden
  2. 2.Uppsala Clinical Research CenterUppsalaSweden
  3. 3.Department of CardiologyLinköping University HospitalLinköpingSweden

Personalised recommendations